---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-097239"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T01:11:38.490637+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q2 sales $11.4B (+22% YoY); raises full-year revenue guidance to $46.4B-$47.4B

## Summary
- GAAP EPS $0.48; non-GAAP EPS $1.31, up 28% YoY on strong demand recovery.
- KEYTRUDA sales $4.2B (+23%); GARDASIL $1.2B (+88%) driven by pandemic recovery.
- Completed Organon spinoff on June 2; received ~$9B cash distribution.
- Full-year non-GAAP EPS guidance raised to $5.47-$5.57, including ~2% FX benefit.
- FDA approvals for VAXNEUVANCE, KEYTRUDA in TNBC and endometrial carcinoma.

## SEC filing metadata
- accession: 0001104659-21-097239
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465921097239/0001104659-21-097239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465921097239/tm2123400d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-097239
- JSON: https://secwatch.observer/filing/0001104659-21-097239.json
- Plain text: https://secwatch.observer/filing/0001104659-21-097239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.